What is the recommended dosing, administration, monitoring, side effect profile, and contraindications of Lokelma (sodium zirconium cyclosilicate) for treating hyperkalemia in an adult with chronic kidney disease, heart failure, or receiving renin‑angiotensin‑aldosterone system (RAAS) inhibitors?

Lokelma (Sodium Zirconium Cyclosilicate) for Hyperkalemia

Lokelma is a highly selective potassium binder that rapidly lowers serum potassium within 1–2 hours and is FDA-approved for treating hyperkalemia in adults, particularly enabling continuation of life-saving RAAS inhibitors in patients with chronic kidney disease, heart failure, or cardiovascular disease. 1

---

Dosing and Administration

Initial Treatment (Correction Phase)

• Administer 10 g three times daily for up to 48 hours to achieve rapid potassium reduction, with mean decreases of approximately 1.1 mEq/L over 48 hours. 1, 2
• Empty the entire packet contents into approximately 3 tablespoons of water, stir well, and drink immediately; repeat rinsing until no powder remains to ensure the full dose is consumed. 1
• Separate Lokelma from other oral medications by at least 2 hours before or after administration, as it can bind medications throughout the gastrointestinal tract and reduce their absorption. 1, 2

Maintenance Treatment

• Start with 10 g once daily after the correction phase, then adjust based on serum potassium levels and desired target range. 1
• Titrate in 5 g increments at intervals of 1 week or longer, with a maintenance dose range of 5 g every other day to 15 g daily. 1
• Decrease the dose or discontinue if serum potassium falls below the desired target range. 1

Special Population: Chronic Hemodialysis Patients

• Administer Lokelma only on non-dialysis days, starting with 5 g once daily. 1
• For patients with serum potassium > 6.5 mEq/L, consider starting with 10 g once daily on non-dialysis days. 1
• Adjust dosing based on pre-dialysis potassium values after the long inter-dialytic interval, with a maintenance range of 5–15 g once daily on non-dialysis days. 1, 3

---

Monitoring Requirements

Acute Phase

• Assess serum potassium within 48 hours during the correction phase to evaluate response. 1, 4
• Monitor for signs of edema, particularly in patients who should restrict sodium intake or are prone to fluid overload. 1

Maintenance Phase

• Check serum potassium after 1 week during initiation and after any dose adjustment to guide titration and protect against hypokalemia. 1, 3, 2
• Continue regular monitoring at individualized intervals based on chronic kidney disease stage, heart failure status, diabetes, and history of hyperkalemia. 3
• Monitor for peripheral edema due to the sodium content (each 10 g dose contains 1200 mg sodium during correction, 400–1200 mg daily during maintenance). 2, 1

---

Side Effect Profile

Common Adverse Effects

• Gastrointestinal symptoms (constipation, diarrhea, nausea) are the most frequently reported adverse effects. 2, 4
• Edema occurs in a dose-dependent manner: 2% with 5 g, 6% with 10 g, and 14% with 15 g daily. 2

Serious but Rare Complications

• Hypokalemia (serum potassium < 3.0 mEq/L) occurred in only 1% of patients in long-term trials, with 5% experiencing mild hypokalemia (3.0–3.4 mEq/L). 5
• The overall safety profile remained consistent over 12 months of treatment, with no deaths attributed to Lokelma in phase III trials. 5

---

Contraindications and Precautions

Absolute Contraindications

• None listed in the FDA label. 1

Avoid Use In

• Patients with severe constipation, bowel obstruction, or impaction (including abnormal post-operative bowel motility disorders), as Lokelma has not been studied in these conditions and may be ineffective or worsen gastrointestinal symptoms. 1

Use with Caution

• Patients who should restrict sodium intake or are prone to fluid overload (e.g., heart failure, chronic kidney disease) require close monitoring for edema due to the sodium content. 1, 2

---

Clinical Context and Advantages

Enabling RAAS Inhibitor Continuation

• Lokelma permits ongoing use of RAAS inhibitors (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists) in patients with hyperkalemia, preserving their cardiovascular and renal protective effects. 2, 5
• In a 12-month trial, 87% of patients on RAAS inhibitors at baseline continued or had their dose increased, while only 11% discontinued therapy. 5
• Among RAAS inhibitor-naïve participants, 14% were able to initiate therapy while maintaining normokalemia with Lokelma. 5

Superiority Over Older Agents

• Lokelma is preferred over sodium polystyrene sulfonate (Kayexalate) due to superior efficacy, better safety profile (no intestinal necrosis reported), and improved patient tolerability. 2, 3
• Kayexalate is associated with serious gastrointestinal complications (intestinal ischemia, colonic necrosis) that double the risk of severe GI adverse events, with an overall mortality of approximately 33%. 2
• Lokelma is highly selective for potassium and does not cause hypocalcemia or hypomagnesemia, unlike Kayexalate which binds cations non-selectively. 2
• Lokelma is more palatable than Kayexalate, facilitating better patient adherence. 2

Rapid Onset of Action

• Lokelma begins lowering serum potassium within 1–2 hours, making it suitable for more urgent outpatient scenarios, though it should not be used as emergency treatment for life-threatening hyperkalemia. 2, 1, 3
• For life-threatening hyperkalemia with ECG changes, insulin/glucose, beta-agonists, calcium, or dialysis should be used first. 2, 3

---

Common Pitfalls to Avoid

• Do not use Lokelma as emergency treatment for life-threatening hyperkalemia (potassium ≥ 6.5 mEq/L with ECG changes), as its onset of action is delayed compared to insulin/glucose or dialysis. 1, 2
• Do not administer Lokelma simultaneously with other oral medications—separate by at least 2 hours to prevent reduced absorption of other drugs. 1, 2
• Do not overlook sodium content—each 10 g dose contains significant sodium (1200 mg during correction, 400–1200 mg daily during maintenance), requiring monitoring for edema in at-risk patients. 2, 1
• Do not discontinue RAAS inhibitors permanently in patients with cardiovascular disease or proteinuric chronic kidney disease who develop hyperkalemia—instead, use Lokelma to enable continuation of these life-saving medications. 3, 2, 5
• Do not fail to monitor for hypokalemia—although rare (1%), it can be more dangerous than hyperkalemia and requires dose reduction or discontinuation. 3, 5